• Neuronostics

  Participated · Equity · Jun 2026

  Neuronostics develops BioEP, a clinically validated digital biomarker platform that analyses standard EEG recordings using eight predefined computational biomarkers and produces a report in under five minutes. The platform is UKCA-marked and ISO-13485 certified and has been validated across 15 NHS sites with over 1,000 recordings. NHS service evaluations are underway at multiple Trusts, including The Royal Wolverhampton NHS Trust and University Hospitals Dorset, and the company has a strategic partnership with Stratus to support scalable US deployment. Neuronostics plans to pursue FDA clearance (with a submission planned for 2026) and to extend the platform to provide brain fingerprints of treatment response in pharmaceutical trials. The company highlights clinical needs such as long diagnostic wait times, high misdiagnosis rates, and the high rate of inconclusive routine EEGs as drivers for its adoption.

• Neubond

  Participated · Seed · Jun 2026

  Neubond develops a forearm-worn wristband and companion app that detect faint muscle electrical signals and deliver sensory biofeedback to help rebuild neural connections after stroke. The platform was developed from over a decade of research in Imperial College London’s Neuromechanics and Rehabilitation Technology lab and was founded by Dr Patrick Sagastegui Alva and Jumpei Kashiwakura with Professor Dario Farina as a co-founder. In a 15-patient pilot, users experienced a 30% increase in range of motion after one month, and the company is running a clinical feasibility study at Charing Cross Hospital to prepare for a randomized controlled trial. Neubond raised £1.5 million in seed funding to finalise the device, pursue MHRA certification, and support its clinical programme. The company is positioning its regulatory and commercial approach toward NHS adoption and exploring broader applications of its neural interface in areas like exoskeleton control.

• Panda Surgical

  Participated · Equity · Oct 2025

  Panda Surgical is a London-based medical device company building a novel handheld robotic system intended for confined-space neurosurgery. Its platform pairs the familiarity of manual tools with detachable, wristed robotic instruments as small as 3 mm in diameter, aiming to let surgeons perform more precise and complex brain and spine operations. Recent milestones include successful worldwide cadaver labs, animal trials, and the expansion of its patent portfolio. The company plans to apply its latest funding toward its first-in-human clinical investigation and continued product development. Leadership believes the technology can broaden global access to advanced surgical care by shrinking the cost and footprint of traditional robotics. Although still pre-revenue, Panda Surgical’s early clinical and technical validation has attracted both institutional and strategic clinician investors.

• Atto

  Participated · Seed · Apr 2012

  Atto operates a credit and risk platform that combines bank data, unique insight engines and advanced modelling to give decision makers a comprehensive view across the credit lifecycle. The company obtains data, with explicit consent, directly from consumers' bank accounts, which it says is real-time, verified and incorruptible. Atto’s insights enable faster, more accurate and personalised credit decisions than traditional credit-reference or self-declared information. The platform powers some of the world’s largest brands and serves banking, consumer and SME lending, utilities, gambling and gaming, the gig economy and other sectors. Based in the UK, Atto reports over 13,000 bank connections giving access to 1.5bn users in more than 45 countries and has doubled both headcount and revenue over the last year. The company completed a $3M bridge round to fund ambitious growth plans and international expansion. MiiCard provides an online identity verification service that validates users by linking to their online bank accounts and other accounts rather than relying solely on self-attested information. The system uses Yodlee for its banking connectivity and is VeriSign Trusted and TRUSTe certified. Users can attach social networking accounts and place their MiiCard on marketplaces or profiles (for example eBay, Craigslist, or Twitter). The company recently launched a third-party Twitter validation system to let any user verify their account. MiiCard currently operates in North America, the U.K., South Africa, India, Australia, and New Zealand and is negotiating partnerships with banks. The company plans to use its new funding to move into the U.S. market. Owned and managed by the individual, miiCard provides a digital passport that allows consumers to track, monitor and take control of their online identity in real time. The service is planned to launch in beta before the 2011 Christmas retail season. Consumer access will cost £1 a month, with vendors charged on a transactional basis. The company completed a management buyout in conjunction with its fundraising. In the transaction James Varga, the founder, was appointed CEO. The company is based in Edinburgh, UK.

• Surrey NanoSystems

  Led · Equity · Mar 2012

  Surrey NanoSystems produces nanostructured materials such as carbon nanotubes and graphene using a proprietary low-temperature synthesis technology and custom-built equipment. The low-temperature capability enables these materials to be applied to lightweight, temperature-sensitive structures where conventional synthesis would be too hot. The company developed Vantablack®, launched at the Farnborough International Air Show in 2014, which absorbs 99.96% of incident radiation. Surrey NanoSystems was spun out of the University of Surrey in 2006. It has raised around £8m in equity funding to date alongside substantial non-dilutive grant funding. Parkwalk first invested in the company in 2012 and has provided a follow-on investment via the Parkwalk Opportunities EIS Fund and a Parkwalk Syndicate. Surrey NanoSystems, based in Newhaven, UK, develops processes and materials to enable use of nanomaterials in semiconductor fabrication, clean tech and renewable industries. The company has created a new class of high‑performance dielectric material for inter‑layer or inter‑metal insulation that offers an alternative to current ‘low k’ materials and resists the liquid chemicals used in semiconductor processing. It also develops a process for growing carbon‑based interconnections or ‘vias’. Surrey NanoSystems provides tools to support nanomaterial research and development at partner sites. The company is led by CEO David Wong and Chairman Lars McBride. The firm raised capital to commercialize its dielectric thin film and the carbon‑via growth process.

No current team members are available.